Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: inflammation, cardiovascular
- Who it enrolls
- age 18 Years to no upper limit; no BMI minimum stated; conditions: Acute Myocardial Infarction With ST Elevation
- Interventions
- Dapagliflozin 10 MG Oral Tablet; Semaglutide (Rybelsus®)
- Conditions
- Acute Myocardial Infarction With ST Elevation
- Phase and size
- Phase 3 · 44 participants
- Dates
- Start 2025-12-30
Primary completion 2026-08 - Sponsor
- Instituto Mexicano del Seguro Social (Other gov)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Inflammatory markers (high-sensitivity PCR)24 weeks.
- Inflammatory markers (interleukin 6)24 weeks
02Eligibility
Who can take part
Inclusion Criteria: * Criteria for the fourth definition of acute myocardial infarction with ST-segment elevation. * Diagnosed with type 2 diabetes. * Initial serum high-sensitivity CRP value \> 2.0 mg/L. * Clinically obese. * LVEF \>50%. Exclusion Criteria: * Patients who have recently received immunosuppressive therapy * Patients with a history of ischemic heart disease * Known allergy to any of the medications used * Use of any of the study drugs more than 6 months prior to randomization * Patients experiencing diabetic ketoacidosis * Patients with hemodynamic instability (mean arterial pressure \<60 mmHg while on vasopressors) * Pregnant women * Patients with a history or current diagnosis of cancer * Patients with documented active infections, such as pneumonia or urinary tract infections * Patients with pancreatitis
03Change log
Registry changes
No changes recorded since the trial was added.